Zoetis Inc. (ZTS) Stock Analysis

Company Overview

Zoetis Inc. (ZTS) carries a market capitalisation of $31.33B. The company sits in the Healthcare sector, in the Drug Manufacturers - Specialty & Generic industry. The company reports 14,500 employees.

ZTS last closed at $75.81 on September 4, 2026. That is −$0.48 (−0.63%) against the previous close. Over the past 52 weeks the price has ranged from $71.00 to $152.97. The latest close sits 6.77% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $9.47B. That is +2.28% against the prior fiscal year, when revenue was $9.26B. Net income for the same year was $2.67B. That is +7.52% against the prior fiscal year. Profit margin runs at 27.69%. That is 30.8 percentage points above the Drug Manufacturers - Specialty & Generic median of −3.14%. Earnings per share on a trailing basis come to 6.1.

Across the 4 fiscal years on file, revenue moves from $8.08B in 2022 to $9.47B in 2025. Of those 4 years, 4 report positive net income.

Valuation Assessment

ZTS trades at a trailing price-to-earnings ratio of 12.43. That is 35.48% below the Drug Manufacturers - Specialty & Generic median of 19.27. On forward earnings the ratio is 11.61. The PEG ratio, which sets the P/E against expected earnings growth, reads 7.1. Measured against sales, the shares trade at 3.29 times revenue. On price-to-sales that is 43.23% above the Drug Manufacturers - Specialty & Generic median of 2.3. 103 Drug Manufacturers - Specialty & Generic companies report these metrics, and the medians quoted come from that group.

The trailing one-year price return is −49.57%. Across 10 years the annualized return works out at +4.91%. The reported beta is 0.73. Daily returns over the trailing 10 years annualize to a volatility of 27.42%.

Growth & Income

ZTS pays a dividend yielding 2.78%. That is 0.7 percentage points above the Drug Manufacturers - Specialty & Generic median yield of 2.06%. The indicated annual rate is $2.12 a share. The ex-dividend date on file is July 20, 2026. Dividends are recorded for 11 calendar years; 2026 shows 3 payments totalling $1.59 a share. The year before, 2025, totalled $2.00 a share.

2026 is still running; the price is −38.80% year to date. Across the complete calendar years on file, 2019 returned +55.71% and 2022 returned −39.51%. Of the 9 complete calendar years on file, 6 finished higher.